
The Lancet Haematology
Fecha de publicación: 19 de enero de 2021
DOI: https://doi.org/10.1016/S2352-3026(20)30429-4
Autores: Akshay Sharma, MBBS, Neel S Bhatt, MBBS, Andrew St Martin, MS, Muhammad Bilal Abid, MD, Jenni Bloomquist, MS, Roy F Chemaly, MD, Christopher Dandoy, MD, Jordan Gauthier, MD, Lohith Gowda, MD, Miguel-Angel Perales, MD, Prof Stuart Seropian, MD, Bronwen E Shaw, MD, Eileen E Tuschl, DNP, Amer M Zeidan, MBBS, Marcie L Riches, MD †, Gunjan L Shah, MD
Background: Haematopoietic stem-cell transplantation (HSCT) recipients are considered at high risk of poor outcomes after COVID-19 on the basis of their immunosuppressed status, but data from large studies in HSCT recipients are lacking. This study describes the characteristics and outcomes of HSCT recipients after developing COVID-19.
Leer más
Comentarios
Para dejar un comentario antes debes iniciar sesión:
¿No tienes una cuenta?
Regístrate a través de éste enlace.